EP2344161 - COMBINATIONS OF A LIPOSOMAL WATER-SOLUBLE CAMPTOTHECIN WITH CETUXIMAB OR BEVACIZUMAB [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 25.10.2019 Database last updated on 03.09.2024 | |
Former | The patent has been granted Status updated on 16.11.2018 | ||
Former | Grant of patent is intended Status updated on 30.07.2018 | ||
Former | Examination is in progress Status updated on 10.08.2017 | Most recent event Tooltip | 01.07.2022 | Lapse of the patent in a contracting state New state(s): MK | published on 03.08.2022 [2022/31] | Applicant(s) | For all designated states Celator Pharmaceuticals, Inc. 200 Princeton South Corporate Center, Suite 180 Ewing, NJ 08628 / US | [2016/51] |
Former [2011/29] | For all designated states Celator Pharmaceuticals Corporation 1779 West 75th Avenue Vancouver, British Columbia V6P 6P2 / CA | Inventor(s) | 01 /
TARDI, Paul 16348 60th Avenue Surrey, British Columbia V3S 1S4 / CA | 02 /
MAYER, Lawrence 2416 Carmaria Court North Vancouver British Columbia V7J 3M4 / CA | 03 /
BERMUDES, David 2081 Adobe Canyon Road Kenwood CA 95452 / US | [2018/51] |
Former [2011/29] | 01 /
TARDI, Paul 19081 Sundale Court Surrey British Columbia V3S 7M6 / CA | ||
02 /
MAYER, Lawrence 2416 Carmaria Court North Vancouver British Columbia V7J 3M4 / CA | |||
03 /
BERMUDES, David 2081 Adobe Canyon Road Kenwood CA 95452 / US | Representative(s) | V.O. P.O. Box 87930 2508 DH Den Haag / NL | [2018/51] |
Former [2011/29] | Jansen, Cornelis Marinus, et al VEREENIGDE Johan de Wittlaan 7 2517 JR Den Haag / NL | Application number, filing date | 09820164.3 | 16.10.2009 | [2011/29] | WO2009CA01483 | Priority number, date | US20080106109P | 16.10.2008 Original published format: US 106109 P | [2011/29] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2010043050 | Date: | 22.04.2010 | Language: | EN | [2010/16] | Type: | A1 Application with search report | No.: | EP2344161 | Date: | 20.07.2011 | Language: | EN | The application published by WIPO in one of the EPO official languages on 22.04.2010 takes the place of the publication of the European patent application. | [2011/29] | Type: | B1 Patent specification | No.: | EP2344161 | Date: | 19.12.2018 | Language: | EN | [2018/51] | Search report(s) | International search report - published on: | CA | 22.04.2010 | (Supplementary) European search report - dispatched on: | EP | 12.06.2014 | Classification | IPC: | A61K31/4745, A61K31/496, A61K31/513, A61K31/7072, A61K39/395, A61K9/127, A61P35/00 | [2011/29] | CPC: |
A61K9/127 (EP,US);
A61K31/4745 (EP,US);
A61K31/496 (EP,US);
A61K31/513 (EP,US);
A61K31/7072 (EP,US);
A61K39/39558 (EP,US);
A61P35/00 (EP)
(-)
| C-Set: |
A61K31/4745, A61K2300/00 (EP,US);
A61K31/496, A61K2300/00 (US,EP);
A61K31/513, A61K2300/00 (US,EP);
A61K31/7072, A61K2300/00 (US,EP); | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2018/51] |
Former [2011/29] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR | Extension states | AL | Not yet paid | BA | Not yet paid | RS | Not yet paid | Title | German: | KOMBINATIONEN EINES LIPOSOMALEN WASSERLÖSLICHEN CAMPTOTHECINS MIT CETUXIMAB ODER BEVACIZUMAB | [2011/29] | English: | COMBINATIONS OF A LIPOSOMAL WATER-SOLUBLE CAMPTOTHECIN WITH CETUXIMAB OR BEVACIZUMAB | [2011/29] | French: | COMBINAISONS D'UNE CAMPTOTHÉCINE DE LIPOSOME SOLUBLE DANS L'EAU AVEC DU CETUXIMAB OU DU BEVACIZUMAB | [2011/29] | Entry into regional phase | 11.05.2011 | National basic fee paid | 11.05.2011 | Search fee paid | 11.05.2011 | Designation fee(s) paid | 11.05.2011 | Examination fee paid | Examination procedure | 11.05.2011 | Examination requested [2011/29] | 19.12.2014 | Amendment by applicant (claims and/or description) | 06.04.2016 | Despatch of a communication from the examining division (Time limit: M06) | 22.08.2016 | Reply to a communication from the examining division | 31.07.2017 | Despatch of a communication from the examining division (Time limit: M04) | 27.10.2017 | Reply to a communication from the examining division | 08.05.2018 | Despatch of a communication from the examining division (Time limit: M04) | 18.06.2018 | Reply to a communication from the examining division | 31.07.2018 | Communication of intention to grant the patent | 05.11.2018 | Fee for grant paid | 05.11.2018 | Fee for publishing/printing paid | 05.11.2018 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 06.04.2016 | Opposition(s) | 20.09.2019 | No opposition filed within time limit [2019/48] | Fees paid | Renewal fee | 11.10.2011 | Renewal fee patent year 03 | 11.10.2012 | Renewal fee patent year 04 | 14.10.2013 | Renewal fee patent year 05 | 14.10.2014 | Renewal fee patent year 06 | 12.10.2015 | Renewal fee patent year 07 | 11.10.2016 | Renewal fee patent year 08 | 11.10.2017 | Renewal fee patent year 09 | 11.10.2018 | Renewal fee patent year 10 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 16.10.2009 | AT | 19.12.2018 | CY | 19.12.2018 | CZ | 19.12.2018 | DK | 19.12.2018 | EE | 19.12.2018 | FI | 19.12.2018 | HR | 19.12.2018 | LT | 19.12.2018 | LV | 19.12.2018 | MC | 19.12.2018 | MK | 19.12.2018 | MT | 19.12.2018 | NL | 19.12.2018 | PL | 19.12.2018 | RO | 19.12.2018 | SE | 19.12.2018 | SI | 19.12.2018 | SK | 19.12.2018 | SM | 19.12.2018 | TR | 19.12.2018 | BG | 19.03.2019 | NO | 19.03.2019 | GR | 20.03.2019 | IS | 19.04.2019 | PT | 19.04.2019 | [2022/31] |
Former [2021/34] | HU | 16.10.2009 | |
AT | 19.12.2018 | ||
CY | 19.12.2018 | ||
CZ | 19.12.2018 | ||
DK | 19.12.2018 | ||
EE | 19.12.2018 | ||
FI | 19.12.2018 | ||
HR | 19.12.2018 | ||
LT | 19.12.2018 | ||
LV | 19.12.2018 | ||
MC | 19.12.2018 | ||
MT | 19.12.2018 | ||
NL | 19.12.2018 | ||
PL | 19.12.2018 | ||
RO | 19.12.2018 | ||
SE | 19.12.2018 | ||
SI | 19.12.2018 | ||
SK | 19.12.2018 | ||
SM | 19.12.2018 | ||
TR | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
GR | 20.03.2019 | ||
IS | 19.04.2019 | ||
PT | 19.04.2019 | ||
Former [2021/32] | HU | 16.10.2009 | |
AT | 19.12.2018 | ||
CY | 19.12.2018 | ||
CZ | 19.12.2018 | ||
DK | 19.12.2018 | ||
EE | 19.12.2018 | ||
FI | 19.12.2018 | ||
HR | 19.12.2018 | ||
LT | 19.12.2018 | ||
LV | 19.12.2018 | ||
MC | 19.12.2018 | ||
NL | 19.12.2018 | ||
PL | 19.12.2018 | ||
RO | 19.12.2018 | ||
SE | 19.12.2018 | ||
SI | 19.12.2018 | ||
SK | 19.12.2018 | ||
SM | 19.12.2018 | ||
TR | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
GR | 20.03.2019 | ||
IS | 19.04.2019 | ||
PT | 19.04.2019 | ||
Former [2021/26] | AT | 19.12.2018 | |
CY | 19.12.2018 | ||
CZ | 19.12.2018 | ||
DK | 19.12.2018 | ||
EE | 19.12.2018 | ||
FI | 19.12.2018 | ||
HR | 19.12.2018 | ||
LT | 19.12.2018 | ||
LV | 19.12.2018 | ||
MC | 19.12.2018 | ||
NL | 19.12.2018 | ||
PL | 19.12.2018 | ||
RO | 19.12.2018 | ||
SE | 19.12.2018 | ||
SI | 19.12.2018 | ||
SK | 19.12.2018 | ||
SM | 19.12.2018 | ||
TR | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
GR | 20.03.2019 | ||
IS | 19.04.2019 | ||
PT | 19.04.2019 | ||
Former [2020/29] | AT | 19.12.2018 | |
CZ | 19.12.2018 | ||
DK | 19.12.2018 | ||
EE | 19.12.2018 | ||
FI | 19.12.2018 | ||
HR | 19.12.2018 | ||
LT | 19.12.2018 | ||
LV | 19.12.2018 | ||
MC | 19.12.2018 | ||
NL | 19.12.2018 | ||
PL | 19.12.2018 | ||
RO | 19.12.2018 | ||
SE | 19.12.2018 | ||
SI | 19.12.2018 | ||
SK | 19.12.2018 | ||
SM | 19.12.2018 | ||
TR | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
GR | 20.03.2019 | ||
IS | 19.04.2019 | ||
PT | 19.04.2019 | ||
Former [2020/17] | AT | 19.12.2018 | |
CZ | 19.12.2018 | ||
DK | 19.12.2018 | ||
EE | 19.12.2018 | ||
FI | 19.12.2018 | ||
HR | 19.12.2018 | ||
LT | 19.12.2018 | ||
LV | 19.12.2018 | ||
NL | 19.12.2018 | ||
PL | 19.12.2018 | ||
RO | 19.12.2018 | ||
SE | 19.12.2018 | ||
SI | 19.12.2018 | ||
SK | 19.12.2018 | ||
SM | 19.12.2018 | ||
TR | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
GR | 20.03.2019 | ||
IS | 19.04.2019 | ||
PT | 19.04.2019 | ||
Former [2020/13] | AT | 19.12.2018 | |
CZ | 19.12.2018 | ||
DK | 19.12.2018 | ||
EE | 19.12.2018 | ||
FI | 19.12.2018 | ||
HR | 19.12.2018 | ||
LT | 19.12.2018 | ||
LV | 19.12.2018 | ||
NL | 19.12.2018 | ||
PL | 19.12.2018 | ||
RO | 19.12.2018 | ||
SE | 19.12.2018 | ||
SI | 19.12.2018 | ||
SK | 19.12.2018 | ||
SM | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
GR | 20.03.2019 | ||
IS | 19.04.2019 | ||
PT | 19.04.2019 | ||
Former [2019/48] | AT | 19.12.2018 | |
CZ | 19.12.2018 | ||
DK | 19.12.2018 | ||
EE | 19.12.2018 | ||
FI | 19.12.2018 | ||
HR | 19.12.2018 | ||
LT | 19.12.2018 | ||
LV | 19.12.2018 | ||
NL | 19.12.2018 | ||
PL | 19.12.2018 | ||
RO | 19.12.2018 | ||
SE | 19.12.2018 | ||
SK | 19.12.2018 | ||
SM | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
GR | 20.03.2019 | ||
IS | 19.04.2019 | ||
PT | 19.04.2019 | ||
Former [2019/46] | AT | 19.12.2018 | |
CZ | 19.12.2018 | ||
EE | 19.12.2018 | ||
FI | 19.12.2018 | ||
HR | 19.12.2018 | ||
LT | 19.12.2018 | ||
LV | 19.12.2018 | ||
NL | 19.12.2018 | ||
PL | 19.12.2018 | ||
RO | 19.12.2018 | ||
SE | 19.12.2018 | ||
SK | 19.12.2018 | ||
SM | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
GR | 20.03.2019 | ||
IS | 19.04.2019 | ||
PT | 19.04.2019 | ||
Former [2019/39] | CZ | 19.12.2018 | |
EE | 19.12.2018 | ||
FI | 19.12.2018 | ||
HR | 19.12.2018 | ||
LT | 19.12.2018 | ||
LV | 19.12.2018 | ||
NL | 19.12.2018 | ||
PL | 19.12.2018 | ||
RO | 19.12.2018 | ||
SE | 19.12.2018 | ||
SK | 19.12.2018 | ||
SM | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
GR | 20.03.2019 | ||
IS | 19.04.2019 | ||
PT | 19.04.2019 | ||
Former [2019/37] | CZ | 19.12.2018 | |
EE | 19.12.2018 | ||
FI | 19.12.2018 | ||
HR | 19.12.2018 | ||
LT | 19.12.2018 | ||
LV | 19.12.2018 | ||
NL | 19.12.2018 | ||
PL | 19.12.2018 | ||
RO | 19.12.2018 | ||
SE | 19.12.2018 | ||
SM | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
GR | 20.03.2019 | ||
PT | 19.04.2019 | ||
Former [2019/35] | CZ | 19.12.2018 | |
FI | 19.12.2018 | ||
HR | 19.12.2018 | ||
LT | 19.12.2018 | ||
LV | 19.12.2018 | ||
NL | 19.12.2018 | ||
PL | 19.12.2018 | ||
SE | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
GR | 20.03.2019 | ||
PT | 19.04.2019 | ||
Former [2019/33] | FI | 19.12.2018 | |
HR | 19.12.2018 | ||
LT | 19.12.2018 | ||
LV | 19.12.2018 | ||
NL | 19.12.2018 | ||
SE | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
GR | 20.03.2019 | ||
PT | 19.04.2019 | ||
Former [2019/30] | FI | 19.12.2018 | |
HR | 19.12.2018 | ||
LT | 19.12.2018 | ||
LV | 19.12.2018 | ||
NL | 19.12.2018 | ||
SE | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
GR | 20.03.2019 | ||
Former [2019/25] | FI | 19.12.2018 | |
HR | 19.12.2018 | ||
LT | 19.12.2018 | ||
LV | 19.12.2018 | ||
SE | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
GR | 20.03.2019 | ||
Former [2019/23] | FI | 19.12.2018 | |
HR | 19.12.2018 | ||
LT | 19.12.2018 | ||
LV | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
Former [2019/22] | FI | 19.12.2018 | |
LT | 19.12.2018 | ||
BG | 19.03.2019 | ||
NO | 19.03.2019 | ||
Former [2019/21] | FI | 19.12.2018 | |
LT | 19.12.2018 | ||
NO | 19.03.2019 | ||
Former [2019/20] | LT | 19.12.2018 | |
NO | 19.03.2019 | Documents cited: | Search | [YD]WO2004087115 (CELATOR TECHNOLOGIES INC [CA], et al) [YD] 1-15 * the whole document *; | [Y] - S. SATHORNSUMETEE ET AL, "Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan", JOURNAL OF CLINICAL ONCOLOGY, (20080110), vol. 26, no. 2, doi:10.1200/JCO.2007.13.3652, ISSN 0732-183X, pages 271 - 278, XP055121262 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1200/JCO.2007.13.3652 | International search | [Y]WO03030864 (NEOPHARM INC [US], et al); | [Y]WO2004087115 (CELATOR TECHNOLOGIES INC [CA], et al); | [Y]WO2005002546 (SMITHKLINE BEECHAM CORP [US], et al); | [Y]WO2005117877 (HOFFMANN LA ROCHE [CH], et al); | [YP]WO2009024667 (AVENTIS PHARMA SA [FR], et al); | [Y] - KIM ET AL., "Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice", CLIN. CANCER RES., (2006), vol. 12, no. 2, pages 600 - 607, XP008136963 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-05-1325 | [Y] - MAHTANI ET AL., "Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract", ONCOLOGIST, (2008), vol. 13, pages 39 - 50, XP008137142 DOI: http://dx.doi.org/10.1634/theoncologist.2006-0049 | Examination | - OOYAMA A ET AL, "Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts", CANCER LETTERS, NEW YORK, NY, US, vol. 267, no. 1, doi:10.1016/J.CANLET.2008.03.008, ISSN 0304-3835, (20080818), pages 26 - 36, (20080416), XP022797039 DOI: http://dx.doi.org/10.1016/j.canlet.2008.03.008 | by applicant | EP0520722 | EP0564409 | EP0566226 | WO9410202 | WO9503283 | WO9630347 | WO9633980 | WO9702266 | EP0769947 | EP0787722 | WO9730034 | WO9738983 | WO9749688 | WO9811223 | WO9810767 | EP0837063 | US5747498 | WO9835958 | WO9903854 | WO0009495 | WO0027820 | WO0027819 | WO0037502 | WO0059509 | WO0062235 | WO0066125 | US6403569 | WO03028696 | WO2004087115 | - FREI et al., Clin. Cancer Res., (19980000), vol. 4, pages 2027 - 2037 | - FISHER, M. D., Clin Colorectal Cancer, (20010800), vol. l, no. 2, pages 85 - 86 | - FURUTA, T. et al., Gan To Kagaku Ryoho, (19910300), vol. 18, no. 3, pages 393 - 402 | - KIM et al., Clin. Cancer Res., (20060000), vol. 12, no. 2, pages 600 - 607 | - PREWETT, M. et al., Cancer Research, (19990000), vol. 59, pages 5209 - 5218 | - YUAN, F. et al., Proc. Natl. Acad. Sci. USA, (19960000), vol. 93, pages 14765 - 14770 | - ZHU, Z. et al., Cancer Res., (19980000), vol. 58, pages 3209 - 3214 | - MORDENTI, J. et al., Toxicologic Pathology, (19990000), vol. 27, pages 14 - 21 | - O'REILLY, M. S. et al., Cell, (19940000), vol. 79, pages 315 - 328 | - O'REILLY, M. S. et al., Cell, (19970000), vol. 88, pages 277 - 285 | - A.S. Janoff,, Liposomes: Rational Design, Marcel Dekker, Inc. |